Peritoneal Mesothelioma Surgical Studies

Recent peritoneal mesothelioma surgical studies include those involving aggressive surgical management, cytoreductive surgery, peritonectomy and HIPEC, hyperthermic perfusion, and more.

Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy
Gastroentérologie Clinique et Biologique, Volume 31, Issue 10, October 2007, Pages 784-788
Dominique Elias, Valérie Bedard, Tarek Bouzid, Pierre Duvillard, Niaz Kohneh-Sharhi, Bruno Raynard, Diane Goere

Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma.
Alexander HR, Hanna N, Pingpank JF. Department of Surgery, University of Maryland Medical Center, Baltimore, MD 21201, USA. HRAlexander@smail.umaryland.edu.

Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Surgical Metabolism Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.
Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN. Division of Oncology, Columbia University New York, New York, USA. mhesdorffer@curemeso.org

[Updated treatment of peritoneal carcinomas: a review]
Deraco M, Laterza B, Kusamura S, Baratti D. Dipartimento di Chirurgia, Unità Tumori Peritoneali, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano. marcello.deraco@istitutotumori.mi.it

Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D, Kusamura S, Sironi A, Cabras A, Fumagalli L, Laterza B, Deraco M. Department of Surgery, National Cancer Institute, Milan, Italy.

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Department of Surgery, National Cancer Institute, Milan, Italy.

Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Department of Surgery, National Cancer Institute, Milan, Italy.

Cytoreductive surgery followed by intra peritoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: morbidity and mortality with closed abdomen technique.
Kusamura S, Deraco M, Baratti D, Inglese MG, Costanzo P, Favaro M, Manzi R, Gavazzi C. Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan.

Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.
Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. ngusani@psu.edu

[Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications]
Eveno C, Dagois S, Guillot E, Gornet JM, Pocard M. Département médicochirurgical de pathologie digestive, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France.

Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.
Elias D, Bedard V, Bouzid T, Duvillard P, Kohneh-Sharhi N, Raynard B, Goere D. Département de chirurgie générale oncologique, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, Villejuif Cedex.

Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
Harrison LE, Bryan M, Pliner L, Saunders T. Division of Surgical Oncology, UMDNJ-New Jersey Medical School, 185 South Orange Ave, Newark, NJ 07103, USA. L.Harrison@umdnj.edu

[Updated treatment of peritoneal carcinomas: a review]
Deraco M, Laterza B, Kusamura S, Baratti D. Dipartimento di Chirurgia, Unità Tumori Peritoneali, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano. marcello.deraco@istitutotumori.mi.it

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis.
Nesher E, Greenberg R, Avital S, Skornick Y, Schneebaum S. Department of Surgery A, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. e_nesher@bezeqint.net

Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.
Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. ngusani@psu.edu

Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.
van Leeuwen BL, Graf W, Pahlman L, Mahteme H. Department of Surgical Sciences, Akademiska Sjukhuset, Uppsala University Hospital, SE 751 85, Uppsala, Sweden.

Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P. Department of Surgery, Ghent University Hospital, B-9000 Ghent, Belgium, wim.ceelen@ugent.be

Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy.
Sugarbaker PH. Washington Cancer Institute, Washington, DC 20010, USA. paul.sugarbaker@medstar.net

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Department of Surgery, National Cancer Institute, Milan, Italy.

Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma.
Alexander HR, Hanna N, Pingpank JF. Department of Surgery, University of Maryland Medical Center, Baltimore, MD 21201, USA. HRAlexander@smail.umaryland.edu

[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]
Gómez Portilla A, Cendoya I, Muriel J, Olabarria I, Guede N, Moraza N, Fernández E, Martínez de Lecea C, Magrach L, Martín E, Romero E, Aguado I, Valdovinos M, Larrabide I. Servicio de Cirugía, Policlínica San José, Vitoria, Alava, España. agomezpor@teleline.es

A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.
Yan TD, Welch L, Black D, Sugarbaker PH. Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA.

Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Washington Hospital Center, Washington Cancer Institute, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA.

Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases.
Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA.

Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Tuttle TM, Zhang Y, Greeno E, Knutsen A. Division of Surgical Oncology, University of Minnesota Medical Center, 420 Delaware Street SE, Minneapolis, MN 55455, USA. tuttl006@umn.edu

[Malignant mesothelioma: A ten years experience.]
Lopes C, Sotto-Mayor R, Teixeira E, Almeida A. Serviço de Pneumologia, Hospital de Santa Maria, Lisboa.

Cytoreductive surgery followed by intra peritoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: morbidity and mortality with closed abdomen technique.
Kusamura S, Deraco M, Baratti D, Inglese MG, Costanzo P, Favaro M, Manzi R, Gavazzi C. Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan.

An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma.
Deraco M, De Simone M, Rossi CR, Cavaliere F, Difilippo F, Scuderi S, Pilatti P, Kusamura S. Dept. of Surgery, Melanoma Sarcoma Unit, Istituto Nazionale per lo studio e la cura dei tumori, Milan, Italy. marcello.deraco@istitutotumori.mi.it

A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S. Department of Cardiothoracic Surgery, New York University School of Medicine, New York, New York 10016, USA. harvey.pass@med.nyu.edu

Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Department of Surgery, National Cancer Institute, Milan, Italy.

Presence and distribution of sensory nerve fibers in human peritoneal adhesions.
Sulaiman H, Gabella G, Davis MSc C, Mutsaers SE, Boulos P, Laurent GJ, Herrick SE. Department of Medicine, University College London, The Rayne Institute, London, UK.

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW. Division of Surgical Oncology, Creighton University Medical Center, Creighton University, Omaha, NE 68131, USA. jasonfoster@creighton.edu


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376